Back to Peptide Pedia
Growth Hormone
Well Researched

Hexarelin

HEXA

Potent growth-hormone secretagogue.

Also known as: Examorelin

Research dose range100 mcg per dose (research models)
Route studiedSubcutaneous
Study duration1–2× daily, shorter study blocks
Storage2–8 °C reconstituted

Overview

Hexarelin is a synthetic hexapeptide growth-hormone secretagogue studied for potent GH-release and cardiovascular-research applications.

Key research findings

One of the most potent GHRPs by weight, studied for strong GH release and for direct cardiovascular effects via CD36 receptors that are independent of GH. Unlike GHRP-6, it does not strongly stimulate appetite, but it can raise cortisol/prolactin at higher amounts.

Mechanism of action

Activates the ghrelin/GH-secretagogue receptor and is studied for additional cardiac CD36-receptor interactions.

Molecular information

Weight887.0 Da
Length6 amino acids
TypeGrowth-hormone-releasing peptide (GHRP)
Amino-acid sequenceHis-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2

A potent synthetic hexapeptide acting at the ghrelin/GH-secretagogue and CD36 receptors.

Pharmacokinetics

Peak: ~0.3 hoursHalf-life: ~0.5–1 hourCleared: ~8 hours
Peak · 1hHalf-life · 5h

Illustrative relative-concentration model derived from published pharmacokinetic research. Curve is normalized and provided for educational comparison only — not a dosing schedule.

Research applications

  • GH-release research
  • Cardiovascular-signaling studies
  • Secretagogue-pathway investigations

Research protocols

Protocols summarized from published research models. Provided for scientific reference only — not dosing guidance for human use.

Standard referenceAmount: 100 mcgFrequency: 1–2× dailyRoute: Subcutaneous
Short-cycle referenceAmount: 100 mcgFrequency: Daily for limited weeksRoute: Subcutaneous

Observed effects timeline

Aggregated observations reported across research literature. Timing and magnitude vary by model and are not a guarantee of outcome.

  1. Acute (per dose)

    Strong GH pulse reported within ~30 minutes of administration.

  2. Week 2–4

    IGF-1 elevation reported; desensitization can occur with prolonged high use.

Research compatibility

Describes how compounds are studied alongside one another in the literature. Not a recommendation to co-administer.

GHRP-6

Redundant GHRP activity.

Avoid combination

Ipamorelin

Overlapping secretagogue mechanism.

Avoid combination

CJC-1295 (no DAC)

GHRH + GHRP synergy in research.

Requires timing

How to reconstitute

Important

Reconstitute with bacteriostatic water, swirl gently, and refrigerate. Avoid shaking to preserve the peptide.

  1. 1Allow the vial to reach room temperature (15–20 minutes).
  2. 2Swab the stopper with alcohol and let it air dry.
  3. 3Add bacteriostatic water slowly down the vial wall.
  4. 4Swirl gently until dissolved into a clear solution.
  5. 5Refrigerate at 2–8 °C and protect from light.
Open reconstitution calculator

Quality indicators

Uniform white powder

Lyophilized cake should be white to off-white without discoloration.

Clear solution

Reconstitutes to a clear, colorless, particle-free solution.

Cold-chain integrity

Reconstituted solution requires 2–8 °C storage.

Slight clumping

Small clumps that dissolve completely with gentle swirling are acceptable — shipping can cause minor compaction.

Collapsed or melted appearance

Powder that looks collapsed, melted, or stuck to the vial walls may have been exposed to heat in transit.

Cloudy after reconstitution

Persistent cloudiness, particles, or precipitate after gentle mixing can indicate a degraded or contaminated peptide.

Reported observations & safety

Safety signals reported in the research literature. Compiled for scientific awareness — not medical advice.

  • Cortisol and prolactin elevation are reported, more so than with ipamorelin.
  • Desensitization with prolonged high use is noted; shorter cycles are common in research designs.

References & further reading

Hexarelin: GH secretagogue and cardiovascular effects (review)

Preclinical/humanGH + CD36cardiovascular

Review of hexarelin's potent GH-releasing action and GH-independent cardiovascular effects via CD36.

View study

Topics

secretagoguegrowth hormoneghrelin

This entry is provided for educational and informational purposes only. It is not medical advice, a dosing protocol, or a claim of therapeutic benefit. Research compounds are supplied strictly for laboratory and research use — not for human or veterinary consumption.

Research level
Well Researched

Substantial peer-reviewed research across multiple models.

Quick reference
Dose range100 mcg per dose (research models)
RouteSubcutaneous
Duration1–2× daily, shorter study blocks
Storage2–8 °C reconstituted
Half-life~0.5–1 hour
Catalogue status

This compound is part of our educational reference and is not currently stocked. Browse the catalogue for available research-grade peptides.

Browse catalogue